Scot Ebbinghaus
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Oncology 59
- Cancer Immunotherapy and Biomarkers 48
- CAR-T cell therapy research 32
-
- Melanoma and MAPK Pathways 17
- RNA Interference and Gene Delivery 10
- DNA and Nucleic Acid Chemistry 10
- Advanced biosensing and bioanalysis techniques 8
- PI3K/AKT/mTOR signaling in cancer 8
- Co-authors
- Laurence H. Hurley (5 shared papers)Antoni Ribas (31 shared papers)Adil Daud (28 shared papers)Caroline Robert (28 shared papers)Omid Hamid (28 shared papers)Anthony M. Joshua (15 shared papers)F. Stephen Hodi (25 shared papers)Soonmo Peter Kang (22 shared papers)
- Journals
- Journal of Clinical Oncology (42 papers)European Journal of Cancer (7 papers)Clinical Cancer Research (5 papers)Cancer Research (5 papers)Journal for ImmunoTherapy of Cancer (4 papers)
- Partner nations
- United StatesFranceCanada
In The Last Decade
Scot Ebbinghaus
94 papers receiving 6.9k citations
Scot Ebbinghaus's Hit Papers
Peers
Comparison fields: 5 of 113
- Oncology 3.4k
- Hepatology 950
- Immunology 1.4k
- Cancer Research 543
- Molecular Biology 2.6k
Countries citing papers authored by Scot Ebbinghaus
This map shows the geographic impact of Scot Ebbinghaus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scot Ebbinghaus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scot Ebbinghaus more than expected).
Fields of papers citing papers by Scot Ebbinghaus
This network shows the impact of papers produced by Scot Ebbinghaus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scot Ebbinghaus. The network helps show where Scot Ebbinghaus may publish in the future.
Co-authors
The 25 scholars most cited alongside Scot Ebbinghaus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 99 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial Hit paper breakdown → | 2019 | 1340 |
| 2 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Hit paper breakdown → | 2017 | 931 |
| 3 | 2010 | 384 | |
| 4 | 2017 | 346 | |
| 5 | 2005 | 250 | |
| 6 | 2009 | 229 | |
| 7 | 2019 | 221 | |
| 8 | 2015 | 183 | |
| 9 | 2015 | 170 | |
| 10 | 2018 | 164 | |
| 11 | 2019 | 161 | |
| 12 | 2008 | 159 | |
| 13 | 2008 | 157 | |
| 14 | 2017 | 142 | |
| 15 | 2018 | 121 | |
| 16 | 2014 | 109 | |
| 17 | 2016 | 84 | |
| 18 | 2018 | 81 | |
| 19 | 2006 | 79 | |
| 20 | 2007 | 76 |
About Scot Ebbinghaus
Scot Ebbinghaus is a scholar working on Oncology, Molecular Biology, Immunology, Cancer Research and Organic Chemistry, having authored 99 papers that have together received 7.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (48 papers), CAR-T cell therapy research (32 papers), Immunotherapy and Immune Responses (17 papers), Melanoma and MAPK Pathways (17 papers), RNA Interference and Gene Delivery (10 papers), DNA and Nucleic Acid Chemistry (10 papers), Advanced biosensing and bioanalysis techniques (8 papers) and PI3K/AKT/mTOR signaling in cancer (8 papers). The work is most often cited by research in Oncology (3.4k citations), Hepatology (950 citations), Immunology (1.4k citations), Cancer Research (543 citations) and Molecular Biology (2.6k citations). Scot Ebbinghaus has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Laurence H. Hurley, Antoni Ribas, Adil Daud, Caroline Robert, Omid Hamid, Anthony M. Joshua, F. Stephen Hodi, Soonmo Peter Kang, Nageatte Ibrahim and Sadahisa Ogasawara. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Clinical Cancer Research, Cancer Research and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.